Given these encouraging prognostic insights, further basic and translational studies are needed to elucidate GDF15’s role in cardiovascular disease pathophysiology and to evaluate its viability as a therapeutic target for reducing systemic cardiovascular risk in patients with PAD. The gene discussed is GDF15; the disease is cardiovascular disorder.